Products
Comprehensive catalog of pharmaceutical solutions. Browse categories and send inquiries directly.
| Molecule | Drug Class / Mechanism | Oncology Type | Inquiry | |
|---|---|---|---|---|
Enasidenib |
RET / MET / KRAS / IDH Inhibitor | Solid Tumour | ||
|
Molecule
Enasidenib
Therapeutic Category
Targeted Therapy
Oncology Type
Solid Tumour
Drug Class / Mechanism
RET / MET / KRAS / IDH Inhibitor |
||||
Olutasidenib |
RET / MET / KRAS / IDH Inhibitor | Solid Tumour | ||
|
Molecule
Olutasidenib
Therapeutic Category
Targeted Therapy
Oncology Type
Solid Tumour
Drug Class / Mechanism
RET / MET / KRAS / IDH Inhibitor |
||||
Vorasidenib |
RET / MET / KRAS / IDH Inhibitor | Solid Tumour | ||
|
Molecule
Vorasidenib
Therapeutic Category
Targeted Therapy
Oncology Type
Solid Tumour
Drug Class / Mechanism
RET / MET / KRAS / IDH Inhibitor |
||||
Erdafitinib |
FGFR Inhibitor | Solid Tumour | ||
|
Molecule
Erdafitinib
Therapeutic Category
Targeted Therapy
Oncology Type
Solid Tumour
Drug Class / Mechanism
FGFR Inhibitor |
||||
Pemigatinib |
FGFR Inhibitor | Solid Tumour | ||
|
Molecule
Pemigatinib
Therapeutic Category
Targeted Therapy
Oncology Type
Solid Tumour
Drug Class / Mechanism
FGFR Inhibitor |
||||
Futibatinib |
FGFR Inhibitor | Solid Tumour | ||
|
Molecule
Futibatinib
Therapeutic Category
Targeted Therapy
Oncology Type
Solid Tumour
Drug Class / Mechanism
FGFR Inhibitor |
||||
Infigratinib |
FGFR Inhibitor | Solid Tumour | ||
|
Molecule
Infigratinib
Therapeutic Category
Targeted Therapy
Oncology Type
Solid Tumour
Drug Class / Mechanism
FGFR Inhibitor |
||||
Derazantinib |
FGFR Inhibitor | Solid Tumour | ||
|
Molecule
Derazantinib
Therapeutic Category
Targeted Therapy
Oncology Type
Solid Tumour
Drug Class / Mechanism
FGFR Inhibitor |
||||
Rogaratinib |
FGFR Inhibitor | Solid Tumour | ||
|
Molecule
Rogaratinib
Therapeutic Category
Targeted Therapy
Oncology Type
Solid Tumour
Drug Class / Mechanism
FGFR Inhibitor |
||||
Fexagratinib |
FGFR Inhibitor | Solid Tumour | ||
|
Molecule
Fexagratinib
Therapeutic Category
Targeted Therapy
Oncology Type
Solid Tumour
Drug Class / Mechanism
FGFR Inhibitor |
||||
Lirafugratinib |
FGFR Inhibitor | Solid Tumour | ||
|
Molecule
Lirafugratinib
Therapeutic Category
Targeted Therapy
Oncology Type
Solid Tumour
Drug Class / Mechanism
FGFR Inhibitor |
||||
Adavosertib |
DNA Damage Response Inhibitor (WEE1/ATR/CHK1) | Solid Tumour | ||
|
Molecule
Adavosertib
Therapeutic Category
Targeted Therapy
Oncology Type
Solid Tumour
Drug Class / Mechanism
DNA Damage Response Inhibitor (WEE1/ATR/CHK1) |
||||
EnasidenibTargeted Therapy |
|
|
Therapeutic Category
Targeted Therapy
Oncology Type
Solid Tumour
Drug Class / Mechanism
RET / MET / KRAS / IDH Inhibitor |
|
OlutasidenibTargeted Therapy |
|
|
Therapeutic Category
Targeted Therapy
Oncology Type
Solid Tumour
Drug Class / Mechanism
RET / MET / KRAS / IDH Inhibitor |
|
VorasidenibTargeted Therapy |
|
|
Therapeutic Category
Targeted Therapy
Oncology Type
Solid Tumour
Drug Class / Mechanism
RET / MET / KRAS / IDH Inhibitor |
|
ErdafitinibTargeted Therapy |
|
|
Therapeutic Category
Targeted Therapy
Oncology Type
Solid Tumour
Drug Class / Mechanism
FGFR Inhibitor |
|
PemigatinibTargeted Therapy |
|
|
Therapeutic Category
Targeted Therapy
Oncology Type
Solid Tumour
Drug Class / Mechanism
FGFR Inhibitor |
|
FutibatinibTargeted Therapy |
|
|
Therapeutic Category
Targeted Therapy
Oncology Type
Solid Tumour
Drug Class / Mechanism
FGFR Inhibitor |
|
InfigratinibTargeted Therapy |
|
|
Therapeutic Category
Targeted Therapy
Oncology Type
Solid Tumour
Drug Class / Mechanism
FGFR Inhibitor |
|
DerazantinibTargeted Therapy |
|
|
Therapeutic Category
Targeted Therapy
Oncology Type
Solid Tumour
Drug Class / Mechanism
FGFR Inhibitor |
|
RogaratinibTargeted Therapy |
|
|
Therapeutic Category
Targeted Therapy
Oncology Type
Solid Tumour
Drug Class / Mechanism
FGFR Inhibitor |
|
FexagratinibTargeted Therapy |
|
|
Therapeutic Category
Targeted Therapy
Oncology Type
Solid Tumour
Drug Class / Mechanism
FGFR Inhibitor |
|
LirafugratinibTargeted Therapy |
|
|
Therapeutic Category
Targeted Therapy
Oncology Type
Solid Tumour
Drug Class / Mechanism
FGFR Inhibitor |
|
AdavosertibTargeted Therapy |
|
|
Therapeutic Category
Targeted Therapy
Oncology Type
Solid Tumour
Drug Class / Mechanism
DNA Damage Response Inhibitor (WEE1/ATR/CHK1) |
|